GlassScriptPhysician profile
Ny My Tran
NPI 1386246718
$2,628.54
in general payments reported to CMS, 2019-2025
17 companies · $76.16 in 2025
The $76.16 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $773 · 2023: $866 · 2024: $743 · 2025: $76.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.14 |
| Education | $284.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $598.76 | 2021-2024 | Padcev |
| Janssen Biotech, INC. | $383.50 | 2023-2024 | Erleada, Akeega, Darzalex |
| Glaxosmithkline, LLC. | $287.43 | 2022-2024 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $227.33 | 2021-2025 | Reblozyl |
| Mirati Therapeutics, INC. | $184.45 | 2023 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $159.09 | 2022-2023 | Reblozyl |
| Pfizer INC. | $137.15 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $124.99 | 2024 | Monoferric |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.95 | 2023 | |
| Genentech USA, INC. | $82.70 | 2022-2024 | Venclexta |
| Merck Sharp & Dohme LLC | $73.31 | 2021-2023 | Keytruda, Lynparza |
| Janssen Scientific Affairs, LLC | $72.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.77 | 2022-2023 | Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $28.96 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.67 | 2025 | |
| Genzyme Corporation | $21.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ny Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.